Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20884024 | 0.94 | FFAR1 (0.42) | HRH3CYP2D6FFAR1KDM2B | |
| SCHEMBL20883598 | 0.88 | NPSR1 (0.38) | HRH3CYP2D6FFAR1KDM2B | |
| SCHEMBL20883988 | 0.82 | OGA (0.38) | FFAR1 | |
| SCHEMBL1787149 | 0.79 | HRH3 (0.50) | HRH3CYP2D6 | |
| SCHEMBL22543774 | 0.79 | FFAR1 (0.39) | HRH3CYP2D6FFAR1 | |
| SCHEMBL14849216 | 0.79 | L3MBTL3 (0.45) | HRH3CYP2D6 | |
| SCHEMBL10255561 | 0.78 | OGA (0.35) | FFAR1 | |
| SCHEMBL15759170 | 0.77 | HRH3 (0.43) | HRH3CYP2D6KDM2B | |
| SCHEMBL17797555 | 0.77 | HRH3 (0.47) | HRH3CYP2D6 | |
| SCHEMBL20883702 | 0.77 | OGA (0.38) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | HRH3 442/4885CYP2D6 908/4885FFAR1 1750/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | HRH3 442/4885CYP2D6 908/4885FFAR1 1750/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | HRH3 442/4885CYP2D6 908/4885FFAR1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.